Guangzhou JOYO Pharma

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
ROS1Small molecule
Non-Small Cell Lung Cancer
Phase 2
JAK1Small molecule
Atopic Dermatitis

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
October 2027 (1)
FudotinibPhase 3Non Small Cell Lung Cancer
Est. primary completion 2027-10-31 · NCT07154368 · CT.gov ↗
What to watch
2028 (1)
December 2028 (1)
FudotinibPhase 3NSCLC (Advanced Non-small Cell Lung Cancer)
Est. primary completion 2028-12-30 · NCT07816380 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.